Suppr超能文献

重组病毒样颗粒作为丙型肝炎病毒(HCV)B细胞和T细胞表位的载体

Recombinant virus-like particles as a carrier of B- and T-cell epitopes of hepatitis C virus (HCV).

作者信息

Mihailova Marija, Boos Mechthild, Petrovskis Ivars, Ose Velta, Skrastina Dace, Fiedler Melanie, Sominskaya Irina, Ross Stefan, Pumpens Paul, Roggendorf Michael, Viazov Sergei

机构信息

Institute of Virology, Essen University Hospital, Essen 45122, Germany.

出版信息

Vaccine. 2006 May 15;24(20):4369-77. doi: 10.1016/j.vaccine.2006.02.051. Epub 2006 Mar 15.

Abstract

The major aim of the project was the development of virus-like particles (VLP) displaying B- and T-cell epitopes of hepatitis C virus (HCV) proteins. To this end, hepatitis B virus core (HBc) particles were used as a carrier of HCV epitopes. Fragments of HCV genes encoding core (aa 98) and NS3 (aa 155) proteins were fused to the 3' terminus of the truncated HBV core gene. All recombinant plasmids led to relatively high levels of expression of chimeric proteins in E. coli, which resulted in the formation of complete "mature" VLP. Chimeric HBc/HCV VLPs were purified by combination of gel filtration and sucrose gradient centrifugation, and used for immunogenicity studies in mice. All variants of hybrid particles induced high humoral and cellular responses to HBcAg. Immunization with the HBc/HCV core particles led to relatively low antibody and T-cell proliferative responses to HCV core epitopes. The HBc/HCV NS3 particles were able to induce high levels of anti-NS3 antibodies in the absence of proliferative responses to HCV epitopes. Thus, the results of the current study have demonstrated the principal possibility of using VLP on the basis of HBcAg for creation of a new type of HCV-specific immunogen.

摘要

该项目的主要目标是开发展示丙型肝炎病毒(HCV)蛋白B细胞和T细胞表位的病毒样颗粒(VLP)。为此,乙型肝炎病毒核心(HBc)颗粒被用作HCV表位的载体。编码核心蛋白(第98位氨基酸)和NS3蛋白(第155位氨基酸)的HCV基因片段被融合到截短的HBV核心基因的3'末端。所有重组质粒在大肠杆菌中均导致嵌合蛋白的相对高水平表达,这导致形成完整的“成熟”VLP。通过凝胶过滤和蔗糖梯度离心相结合的方法纯化嵌合HBc/HCV VLP,并用于小鼠的免疫原性研究。杂交颗粒的所有变体均诱导了对HBcAg的高体液和细胞反应。用HBc/HCV核心颗粒免疫导致对HCV核心表位的相对较低的抗体和T细胞增殖反应。HBc/HCV NS3颗粒在对HCV表位无增殖反应的情况下能够诱导高水平的抗NS3抗体。因此,当前研究的结果证明了基于HBcAg使用VLP创建新型HCV特异性免疫原的主要可能性。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验